Taro Pharmaceutical
- All
- News
- Videos
-
Sun Pharma Records Rs 2,277 Crore March Quarter Net Loss
Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022
-
Top 5 Pharma Companies Lose 19,000 Crore In Market Value. Here Is Why
Analysts say the fresh selloff in the pharmaceutical shares has been triggered after Sun Pharma's US-based subsidiary Taro Pharmaceuticals reported a weak set of earnings in the March quarter.
-
Sun Pharma Indirect Arm To Acquire Thallion Pharmaceuticals
Thallion Pharmaceuticals had a turnover of Canadian dollar 3.1 million for the year ended December 31, 2016.
-
Dilip Shanghvi, Man Behind India's Best Stock, Now Faces His Greatest Test
Both Shanghvi's eye for value and his tenaciousness were exemplified in the 2010 takeover of Israel-based Taro Pharmaceutical Industries Ltd.
-
US Department Of Justice Summons Taro Over Generic Drugs Pricing
US Department of Justice has sent summons to Sun Pharmaceutical Industries' US arm Taro Pharmaceutical Industries Inc and its two senior executives seeking information on generic drug pricing. has sent summons to Sun Pharmaceutical Industries' US arm Taro Pharmaceutical Industries Inc and its two senior executives seeking information on generic dru...
-
Sun Pharma Shares Jump On Taro's Q4
Sun Pharmaceuticals shares jumped over 5 per cent on Friday after the drugmaker's US-based subsidiary Taro Pharma reported strong earnings.
-
Sun Pharma Shares Hit As Taro Stops Keveyis Sales
Sun Pharmaceuticals Industries' shares fell nearly 4 per cent on Tuesday after its New York Stock Exchange-listed subsidiary Taro Pharmaceutical stopped commercial sales of Keveyis, a drug used in treatment of periodic paralysis.
-
Taro Not to Invest in Wind Energy Project in US
Reversing its earlier decision, drug major Sun Pharmaceutical Industries on Tuesday said its Israeli arm Taro has decided not to proceed with an investment in a wind energy project in the US.
-
Sun Pharma Jumps on New Drug Launch by Taro, Divestment Plans
Sun Pharmaceutical Industries shares jumped as much as 1.6 per cent to hit intraday high of Rs 859.05 on the back of slew of news developments.
-
Sun Pharma Falls; Earnings In Line With Estimates
Sun Pharma's profits were in line with estimates despite hopes of a better show after unit Taro Pharmaceutical Industries reported higher earnings earlier, traders say.
-
Sun Pharma Hits All-time High After Unit Taro's Results
Unit Taro Pharmaceutical Industries' quarterly profit grew by 49 per cent to a record level of $143 million.
-
Sun Pharma Falls; Unit Taro Results Fail to Beat Estimates
Taro's revenue in January-March grew by 13 per cent to $187 million, while profit jumped by 82 per cent to $90 million.
-
Sun Pharma shares gain on US unit earnings
Taro said on Monday that its net sales for October-December grew 15 per cent to $213.6 million and earnings per share was at $2.59 per share.
-
2013: Few bitter pills, booster injections for pharma sector
Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.
-
Sun Pharma gains on Taro's share buyback offer
If the offer is fully subscribed, the number of Taro shares to be purchased in the offer represents approximately 4.6 to 5.3 per cent of the unit's total outstanding shares.
-
Sun Pharma Records Rs 2,277 Crore March Quarter Net Loss
Sun Pharmaceutical Industries on Monday said its consolidated net loss stood at Rs 2,277 crore for the fourth quarter ended March 2022
-
Top 5 Pharma Companies Lose 19,000 Crore In Market Value. Here Is Why
Analysts say the fresh selloff in the pharmaceutical shares has been triggered after Sun Pharma's US-based subsidiary Taro Pharmaceuticals reported a weak set of earnings in the March quarter.
-
Sun Pharma Indirect Arm To Acquire Thallion Pharmaceuticals
Thallion Pharmaceuticals had a turnover of Canadian dollar 3.1 million for the year ended December 31, 2016.
-
Dilip Shanghvi, Man Behind India's Best Stock, Now Faces His Greatest Test
Both Shanghvi's eye for value and his tenaciousness were exemplified in the 2010 takeover of Israel-based Taro Pharmaceutical Industries Ltd.
-
US Department Of Justice Summons Taro Over Generic Drugs Pricing
US Department of Justice has sent summons to Sun Pharmaceutical Industries' US arm Taro Pharmaceutical Industries Inc and its two senior executives seeking information on generic drug pricing. has sent summons to Sun Pharmaceutical Industries' US arm Taro Pharmaceutical Industries Inc and its two senior executives seeking information on generic dru...
-
Sun Pharma Shares Jump On Taro's Q4
Sun Pharmaceuticals shares jumped over 5 per cent on Friday after the drugmaker's US-based subsidiary Taro Pharma reported strong earnings.
-
Sun Pharma Shares Hit As Taro Stops Keveyis Sales
Sun Pharmaceuticals Industries' shares fell nearly 4 per cent on Tuesday after its New York Stock Exchange-listed subsidiary Taro Pharmaceutical stopped commercial sales of Keveyis, a drug used in treatment of periodic paralysis.
-
Taro Not to Invest in Wind Energy Project in US
Reversing its earlier decision, drug major Sun Pharmaceutical Industries on Tuesday said its Israeli arm Taro has decided not to proceed with an investment in a wind energy project in the US.
-
Sun Pharma Jumps on New Drug Launch by Taro, Divestment Plans
Sun Pharmaceutical Industries shares jumped as much as 1.6 per cent to hit intraday high of Rs 859.05 on the back of slew of news developments.
-
Sun Pharma Falls; Earnings In Line With Estimates
Sun Pharma's profits were in line with estimates despite hopes of a better show after unit Taro Pharmaceutical Industries reported higher earnings earlier, traders say.
-
Sun Pharma Hits All-time High After Unit Taro's Results
Unit Taro Pharmaceutical Industries' quarterly profit grew by 49 per cent to a record level of $143 million.
-
Sun Pharma Falls; Unit Taro Results Fail to Beat Estimates
Taro's revenue in January-March grew by 13 per cent to $187 million, while profit jumped by 82 per cent to $90 million.
-
Sun Pharma shares gain on US unit earnings
Taro said on Monday that its net sales for October-December grew 15 per cent to $213.6 million and earnings per share was at $2.59 per share.
-
2013: Few bitter pills, booster injections for pharma sector
Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.
-
Sun Pharma gains on Taro's share buyback offer
If the offer is fully subscribed, the number of Taro shares to be purchased in the offer represents approximately 4.6 to 5.3 per cent of the unit's total outstanding shares.
